Various antiepileptics, sedative and anesthetic agents are used in the neurocritical care setting and therapeutic drug monitoring (TDM) has been proposed as a means to individualize dosing to ensure efficacy, avoid toxicity, and to account for drug-drug interactions. The purpose of this review is to highlight key articles relating to TDM published in the last 5 years with a focus on drug therapy for seizures, status epilepticus, and traumatic brain injury.
Introduction
Therapeutic drug monitoring (TDM) refers to analysis and subsequent interpretation of drug concentrations in biological fluid [1] . TDM may be useful when the drug can be readily measured and has a narrow therapeutic range; a good relationship exists between drug concentration and pharmacologic response that is otherwise not readily assessable; pharmacokinetic parameters are unpredictable; therapy duration is of sufficient length; and drug assay results will make a difference in clinical decisionmaking [1] . Thus, TDM is potentially important for various antiepileptic, anesthetic, and sedative agents used in the neurocritical care setting and may be particularly useful to individualize dosing and identify, prevent, or manage drug interactions.
The purpose of this review is to highlight key articles (published in the past 5 years) on TDM in the neurocritical care setting. Drugs covered under 'Seizure management and status epilepticus' include first and second-generation antiepileptic drugs (AEDs). Drugs covered under 'Traumatic brain injury' are thiopental and pentobarbital; those under 'Sedation' are midazolam, lorazepam, and propofol. We also provide a summary of assay methods and pharmacokinetic characteristics for each drug (Table 1) [2,3 ,4 ,5 ,6 ,7-13] .
Seizure management and status epilepticus
Agents used in seizure management and status epilepticus include first and second-generation AEDs.
First-generation agents
Much of the published TDM literature in neurocritical care has involved AEDs used to manage seizures and status epilepticus. In particular, TDM is routinely utilized as a monitoring parameter for first-generation AEDs due to their narrow therapeutic range, numerous drugdrug interactions and unpredictable pharmacokinetics [2, 5 ] .
Phenytoin
Phenytoin is a first-line agent in generalized tonic-clonic seizures, partial seizures, and status epilepticus. Phenytoin TDM is well established in clinical practice as it has a narrow therapeutic window, high protein binding, nonlinear pharmacokinetics, and interindividual variations in can " midazolam concentrations metabolism. A key issue concerns the utility of measuring free versus total concentrations of phenytoin in critically ill patients [14 ] .
Von Winckelmann et al. [14 ] provide a comprehensive summary of phenytoin pharmacokinetics in the critically ill. Weight-based dosing of phenytoin correlates poorly with serum drug concentrations due to altered drug metabolism and hypoalbuminemia. Also, enteral administration of phenytoin is unreliable as phenytoin may physically bind to various drugs (e.g. sucralfate) and enteral nutrition; intravenous administration is preferred. The authors strongly advocate routine free phenytoin monitoring as phenytoin is extensively bound to serum proteins, has a narrow therapeutic range, volume of distribution less than 2 l/kg, free fraction that can vary even in the therapeutic range, and documented correlation between free serum concentrations and pharmacologic effect. Although theoretical equations (e.g. Sheiner-Tozer) can be used to determine the phenytoin serum concentration that would be observed if albumin levels were normal, their applicability is limited to patients with normal renal function and those not receiving other highly-protein-bound drugs ( Table 2 ) [14 ] .
In 70 patients treated with oral phenytoin, Iwamoto et al. [15] found mean free phenytoin concentration was significantly higher in patients with a complete response to phenytoin than those with a partial response. In contrast, mean total phenytoin concentration was not significantly different between the two groups, suggesting that monitoring free is more useful than total concentration. Factors found to influence free fraction included age, renal function and serum albumin.
Valproic acid
Therapeutic drug monitoring has traditionally been performed on valproic acid (VPA) or divalproex, commonly prescribed for primary generalized tonic-clonic, absence and myoclonic seizures. VPA is extensively bound to albumin, but unlike phenytoin, exhibits concentrationdependent protein binding. Few clinical laboratories [16 ] C N ¼ a H C H /6.5 C N ¼ normalized total concentration of valproic acid a H ¼ free fraction of the drug corresponding to the patient's albuminemia C H ¼ total concentration of valproic acid 6.5 ¼ free fraction of the drug for a serum albumin of 42 g/l (50th percentile of reference range) ($2%) that measure total VPA levels measure free levels [16 ] .
Hermida and Tutor [16 ] derived an equation attempting to normalize total VPA concentrations for albumin using data from 121 hypoalbuminemic patients (receiving VPA for seizures) and previously published free fraction values (Table 2) . For patients with total VPA concentrations less than 75 mg/l (525 mmol/l), the derived equation had a prediction error of 2.5 mg/l or less (17.5 mmol/l). Fortyeight percent of 48 patients with subtherapeutic total VPA levels actually had therapeutic levels once normalized and 48% of 65 patients with therapeutic concentrations became supratherapeutic. Limitations of the formula were inability to apply it to patients with jaundice and uremia as well as progressively increasing prediction errors for total concentrations more than 75 mg/l.
With availability of intravenous VPA in the United States for acute seizure activity and status epilepticus, Dutta et al. [17] , in 40 epileptic patients following rapid infusion of 20-30 mg/kg, found free VPA fraction was approximately 7.5% at a total VPA concentration of 50 mg/l but mean free fraction increased to 22% at a total VPA concentration of 150 mg/l, indicative of nonlinear protein binding. No other covariate (e.g. age, sex, race, and concomitant AEDs) significantly influenced VPA protein binding.
A case report by Chan and Beran [18 ] highlights the utility of measuring free levels of AEDs, particularly with polytherapy. A 66-year-old man taking phenytoin, carbamazepine, VPA, and levetiracetam was admitted with symptoms suggestive of AED toxicity. The initial lab report showed subtherapeutic phenytoin and therapeutic carbamazepine and VPA levels. A levetiracetam level was not performed. The neurologist requested free level measurement of phenytoin, carbamazepine, and VPA, which was met with considerable resistance by laboratory staff. Subsequent TDM, however, showed a supratherapeutic free VPA level and therapeutic free levels of phenytoin and carbamazepine. Total VPA level was 499 mmol/l (therapeutic range 350-700 mmol/l), whereas free level was 93 mmol/l (therapeutic range 30-75 mmol/l). VPA was promptly discontinued and then restarted at a lower dose with total cessation of symptoms. The authors concluded that measurement of free levels of AEDs has a clinical role in epilepsy management when ordered judiciously.
On the basis of these recent studies, monitoring of free VPA levels appears useful in the neurocritical care population, although evidence for routine free-level monitoring is not as robust as for phenytoin. When free VPA level monitoring is not available, the Hermida equation [16 ] would be an alternative as long as its limitations are recognized.
Carbamazepine and phenobarbital
No recent articles on carbamazepine or phenobarbital TDM in neurocritical care patients have been published. A summary of assay methods and pharmacokinetic characteristics is provided in Table 1 .
In summary, routine TDM for first-generation agents appears well established. Recently published articles, however, caution against misinterpretation of total concentrations of highly protein-bound AEDs in the neurocritical care population. Rather, measurement of free drug concentration would be preferred. In case the laboratory does not measure free drug concentrations, equations correcting for low albumin may be used to normalize total measured concentrations before making significant dosage adjustments.
Second-generation agents
Second-generation AEDs are increasingly used as monotherapy or as adjuncts to first-generation agents for seizure control. Potential benefits include more predictable pharmacokinetics and fewer drug-drug interactions and adverse effects. Therefore, the utility of TDM for second-generation agents remains debatable [2].
Lamotrigine
Lamotrigine exhibits efficacy against a wide range of seizure types including partial, primary and secondary generalized tonic-clonic, absence, and Lennox-Gastaut syndrome. Utility of routine TDM remains controversial, mainly because a clear relationship between concentration and pharmacologic response has not been fully demonstrated [19] .
In a retrospective review of 20 patients who received lamotrigine prior to surgery, Paul et al. [20] found a 20% decrease in lamotrigine levels in 16 patients postoperatively. Six patients experienced seizures in the first 2 weeks postsurgery and in three patients, seizure coincided with lamotrigine serum level nadir. The authors concluded that future prospective studies and a standardized approach to perioperative management of AEDs in patients undergoing epilepsy surgery are needed. A proposed regimen was preoperative dose augmentation followed by postoperative lamotrigine levels every 2 days for up to 2 weeks and reduction in dose 2 weeks postoperatively. The difficulty with applying this recommendation in practice is that target levels are not well defined.
Levetiracetam
Levetiracetam, originally indicated for refractory partial seizures with or without secondary generalization, is now increasingly used for various seizure types. Levetiracetam has minimal binding to plasma proteins, no active metabolites, lack of significant drug-drug interactions and is predominantly renally eliminated [5 ] . Recent availability of a parenteral formulation of levetiracetam in the United States increases its likelihood of use for acute seizures and status epilepticus [21] . A recent retrospective analysis of an American neurocritical care unit found that patients with acute brain injury, whose seizures were treated with levetiracetam, had significantly shorter stays and fewer complications than phenytoin [22] .
In a retrospective chart review of 81 plasma samples from 69 patients with severe, refractory epilepsy, Lancelin et al. [23] found that levetiracetam trough concentrations of patients receiving 500-3000 mg/day ranged from 1 to 33.5 mg/ml (5.8-194 mmol/l). Large interindividual variability was observed in serum levels of patients receiving the same dosage. Patients with !50% reduction in seizure frequency were considered responders and <50% reduction were partial responders; those exhibiting no improvement were considered nonresponders. Mean levetiracetam serum level in responders was 12.9 mg/ml compared to 9.5 mg/ml in nonresponders and 12.4 mg/ml in partial responders. Wide variability in concentrationresponse relationship was also observed. Threshold concentration for a therapeutic response was 11 mg/ml (sensitivity of 73% and specificity of 71%; P > 0.05). The authors concluded that monitoring of levetiracetam concentrations did not appear necessary in patients experiencing improvement in their seizure disorder, but may help verify compliance or detect severe toxicities.
With recent availability of a parenteral levetiracetam formulation, Uges et al. [21] evaluated feasibility of adjunctive i.v. levetiracetam for status epilepticus. Twelve patients received 2.5 g of levetiracetam in addition to conventional agents (benzodiazepine followed by phenytoin or VPA) as per protocol. No serious toxicities attributable to levetiracetam were observed over the next 24 h. Using serum samples from 10 patients, levetiracetam pharmacokinetics was best characterized by a two-compartment population model with volume of distribution of 0.45 l/kg and mean maximal plasma concentration of 85 mg/ml, findings that corresponded closely to those from healthy volunteers.
Oxcarbazepine
Oxcarbazepine, a 10-keto derivate of carbamazepine, is indicated in partial or generalized tonic-clonic seizures either as monotherapy or adjunctive therapy.
Since oxcarbazepine is a pro-drug that is rapidly metabolized, its primary metabolite, the monohydroxylated derivative (MHD), is measured. On the basis of a vali-dated decision-making algorithm, Bring and Ensom [3 ] found MHD to have a wide therapeutic range and poor correlation between concentration and clinical response. Although patients receiving oxcarbazepine for a prolonged period of time may be appropriate candidates for TDM, other clinical monitoring parameters are available. However, TDM may be considered in patients who are at the extremes of age or pregnant; those who may be noncompliant or report therapeutic failure; or those with renal dysfunction or taking known interacting drugs.
Pregabalin
Pregabalin, like gabapentin, is structurally related to the neurotransmitter gamma-aminobutyric acid. Although used predominantly for neuropathic pain, it is also used for partial with and without generalized tonic-clonic seizures.
In a retrospective study by May et al. [24] , analysis of covariance (of 198 pregabalin samples from 167 patients with epilepsy) showed that pregabalin concentrations were 20-30% lower with concomitant enzyme-inducing AEDs such as carbamazepine or phenytoin. Pregabalin serum concentrations were also higher in older patients as is expected with predominantly renally excreted drugs. Despite these findings, utility of pregabalin TDM warrants further study since the concentration-efficacy relationship remains unclear.
Topiramate
Topiramate has been studied as a second-line AED for primary and secondarily generalized tonic-clonic as well as absence seizures. It has a linear pharmacokinetic profile with no active metabolites, minimal plasma protein binding and is primarily renally excreted [5 ].
Zanotta et al. [25] examined relevance of topiramate serum level monitoring in clinical practice; 43 levels were obtained from 27 patients with various epileptic conditions. Mean dose was 3.9 mg/kg and concentration 4.5 mg/l (13.4 mmol/l). Four patients became seizure-free but all received lower than the mean dosage. Eleven patients had a 50% decrease in seizure frequency. Comedication with enzyme-inducing AEDs significantly decreased topiramate serum levels, with mean level-todose ratio of 5.3 versus 2.9 mmol/l/mg/kg, respectively. A direct relationship could neither be confirmed between high topiramate levels and seizure control nor tolerability. The authors concluded that routine topiramate serum monitoring is unnecessary except when noncompliance is suspected or when topiramate kinetics are affected by other drugs or disease (e.g. renal failure).
Gabapentin, vigabatrin, felbamate
No recent pertinent articles on gabapentin, vigabatrin, and felbamate TDM in neurocritical care patients have been published. A summary of assay methods and pharmacokinetic characteristics is provided in Table 1 .
There appears to be a lack of evidence to support routine TDM of second-generation AEDs in the neurocritical care setting. Due to linear kinetics, negligible proteinbinding, lack of significant drug-drug interactions and availability of other readily obtainable clinical monitoring parameters, TDM should be reserved for patients who are very young or old, experiencing therapeutic failure that may be attributed to sub-therapeutic drug concentrations, with acute renal dysfunction, receiving concomitant enzyme-inducing AEDs, or with suspected noncompliance. However, target levels have not been clearly established nor are assays readily available.
Traumatic brain injury and seizure prophylaxis
Current therapeutic strategies in traumatic brain injury (TBI) management include use of AEDs for seizure prophylaxis in high-risk patients [26] . In patients who develop refractory elevated intracranial pressure (ICP) from inflammation postinjury or who have concerns with cerebral ischemia, intravenous sedation such as barbiturates or benzodiazepines may be necessary to suppress brain activity. TDM of these agents may be of some benefit in TBI patients to ensure adequate sedation but not toxic concentrations that may suppress central nervous system or respiratory activity [26] .
Seizure prophylaxis
Phenytoin has traditionally been used for seizure prophylaxis after high-risk neurosurgical procedures, but availability of safer agents is challenging this practice. Current recommendations are to taper off AEDs used for seizure prophylaxis in patients with brain tumor or TBI approximately 1 week postoperatively or postinjury [26] . Milligan et al. [27 ] conducted a retrospective review in patients who received either intravenous levetiracetam or phenytoin as monotherapy for seizure prophylaxis postcraniotomy. Approximately 21-31% of patients experienced preoperative seizure activity. Patients (n ¼ 105) on levetiracetam did not receive TDM; of patients (n ¼ 201) on phenytoin, 180 received TDM with a median level of 11 mg/l (44 mmol/l). One patient on levetiracetam and eight on phenytoin experienced postoperative seizure (median level in phenytoin group was 13.5 mg/l or 54 mmol/l). Both drugs were associated with low risk of postoperative seizures and moderate risk of epilepsy development but significantly more patients who received phenytoin required change in therapy due to adverse effects during hospitalization. Levetiracetam may be a viable alternative to phenytoin for seizure prophylaxis, although further prospective studies are recommended.
Traumatic brain injury
Due to lack of clinically evaluable efficacy parameters and high risk of oversedation, TDM has been sporadically used to assess efficacy and toxicity of various sedation agents used in post-TBI patients [26] . Since these drugs completely suppress brain activity and induce a comatose state, TDM has also been proposed as a tool to rule out therapeutic drug concentrations when making a diagnosis of brain death.
Huynh et al.
[4 ] reviewed utility of TDM for thiopental continuous infusion in the critical care population using a previously published decision algorithm. The studies suggested a poor relationship between thiopental concentrations and pharmacological response, including neurological signs and symptoms, ICP, electroencephalography readings, and drug toxicity. Furthermore, a wide and overlapping range of levels, reported for thiopental continuous infusion, corresponded to efficacy and toxicity. Pharmacokinetic parameters also exhibited wide intrapatient and interpatient variability. The authors concluded that thiopental TDM may be warranted in two clinical scenarios: to provide patient-specific target plasma concentration to help guide therapy and to help differentiate between barbiturate coma and brain death.
Due to legal and ethical implications of diagnosing brain death, and regular use of sedative and anesthetic agents in neurocritical care that may closely mimic brain death, several investigators [12, 13] have recently developed assays to measure common sedative and anesthetic agents and their metabolites. There is general agreement that diagnosis of brain death can be made if drug levels are below the therapeutic range. However, defined therapeutic ranges have not been clearly established.
In summary, utility of TDM for patients receiving seizure prophylaxis in the neurocritical care setting appears to be diminishing with availability of newer agents that exhibit more predictable pharmacokinetics. In TBI patients, routine TDM of barbiturate continuous infusion appears to be of limited value, except in situations when an accurate diagnosis of brain death is required.
Sedation
Sedative agents [e.g. benzodiazepines (midazolam, lorazepam) and propofol] are frequently administered in neurocritical care settings to facilitate mechanical ventilation, perform routine medical procedures and nursing care, manage withdrawal states, and allow patients to remain calm, cooperative, and communicative to enhance neurologic recovery [28] . Regular monitoring of sedation is essential in interpreting a patient's neurological status and function due to the fine balance between adequate and oversedation. Consequences of oversedation include impairment of neurological recovery, prolonged hospitalization, and adverse effects on the cardiopulmonary system. Thus, TDM of sedative agents has been proposed as one way to customize a patient's sedation requirements.
Midazolam
Midazolam, a short-acting, rapid onset benzodiazepine, is frequently administered intravenously as a sedative agent in neurocritical care. There is potential for the propylene glycol diluent in parenteral preparations to accumulate and cause toxicity when lorazepam is administered in high doses. Yahwak et al. [29] investigated a threshold dose for parenteral lorazepam by measuring osmol gap as a screening tool for propylene glycol toxicity (kidney injury, metabolic acidosis). A measured osmol gap of at least 10 had a likelihood ratio of 4.4 to predict elevated propylene glycol levels and an osmol gap of more than 12 had a likelihood ratio of 2.7 to predict propylene glycol toxicity. The authors recommended screening for propylene glycol toxicity in patients receiving at least 1 mg/kg/day of intravenous lorazepam. Nelsen et al. [30] prospectively followed propylene glycol levels in 50 critically ill patients receiving lorazepam continuous infusion for more than 18 h. In this patient cohort, although median lorazepam infusion rate was low (2.1 mg/h), 16% of patients had significant propylene glycol concentrations higher than 21 mg/dl; these concentrations appeared to correlate poorly with osmolality, osmol gap, and lactate levels.
Propofol
Propofol, an intravenous sedative and anesthetic, has become increasingly used in neurocritical care due to its favorable pharmacokinetic profile. With its short halflife, propofol can be quickly titrated as a continuous infusion to attain target sedation level; neurological signs and symptoms can also be quickly assessed shortly after propofol infusion is stopped with less risk of drug accumulation versus benzodiazepines [28] . As a sedative in mechanically ventilated patients, Carson et al. [31] found that patients on propofol spent significantly fewer days on mechanical ventilation compared to lorazepam (median: 5.8 versus 8.4 days, respectively; P ¼ 0.04). A meta-analysis by Ho and Ng [32] found that use of propofol for medium or long-term sedation appeared well tolerated and significantly decreased duration of stay in critical care (P ¼ 0.0002).
No studies pertaining to utility of propofol TDM were found with the exception of studies measuring levels in patients with potential brain death. Despite its excellent pharmacokinetic profile, propofol has been associated with a potentially fatal adverse effect known as propofol-related infusion syndrome [33] , characterized by acute onset of bradycardia or dysrhythmias in the presence of lipemic plasma, metabolic acidosis, and possibly rhabdomyolysis or myoglobinuria. Risk factors include propofol continuous infusions of at least 5 mg/kg/h for more than 48 h, serious cerebral injury or sepsis. Patients requiring prolonged propofol infusions are recommended to receive regular hemodynamic, electrocardiogram, arterial blood gas, and triglyceride monitoring [33] .
Current literature does not appear to support routine TDM for sedative agents in the neurocritical care setting. Clinical sedation scales appear to be most effective in determining a patient's target level of sedation and whether oversedation has occurred. TDM of sedative agents may be considered when trying to rule out brain death or in patients with significant hepatic or renal failure who fail to awaken after administration of sedation.
Conclusion
TDM plays an important role for patients in the neurocritical care setting but is applicable only to a limited number of drugs. TDM for first-generation AEDs is well established and free drug concentrations are preferred for phenytoin and VPA. However, there is a lack of evidence to support routine TDM for second-generation AEDs. For TBI patients, TDM of barbiturate continuous infusions appears to be of limited value, except when accurate diagnosis of brain death is required. Current literature does not appear to support routine TDM for sedative agents used in the neurocritical care setting and clinical sedation scales appear to be most effective in determining a patient's target level of sedation.
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